Skip to main content
Clinical Trials/NCT00916955
NCT00916955CompletedNot Applicable

Genetic Modifiers for 22q11.2 Syndrome

State University of New York - Upstate Medical University1 site in 1 countryStarted: March 2008Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Locations
1
Primary Endpoint
gene signal strength

Study Overview

Brief Summary

The purpose of the project is the determination of how the deletion of DNA from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In other words, the purpose remains genotype-to-phenotype matching. Current methods includes the use of whole genome chips and microarray analysis. Blood samples are collected for DNA from every patient who consents from the VCFS Center at Upstate Medical University. They are examined for phenotypic features consistent with our typical clinical evaluation. The information from these examinations will be entered anonymously into a database. Genomic information is then matched to clinical phenotype with appropriate statistical method applied.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • FISH confirmed diagnosis of 22q11.2 deletion syndrome

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

gene signal strength

Time Frame: 4 years

Secondary Outcomes

  • physical phenotype(4 years)

Investigators

Sponsor
State University of New York - Upstate Medical University
Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials